Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-708163 in prodromal Alzheimer's disease
NL-OMON33225Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing BMS-708163 with Placebo (2 arms). Primary endpoint: Safety and tolerability of BMS-708163. Started Oct 2009; status: active, not recruiting.
02
Drugs
avagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON33225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33225.